Ligand Pharmaceutical Inc (LGND) Com Stk Class 'B' USD0.001
0.18%- This stock can be held in a
Stocks and Shares ISA
$1.64
(1.38%)$1.64
(1.38%)Company Information
About this company
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Key people
Key facts
- EPIC-
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS53220K5048
- Market cap$2.23bn
- Employees58
- Shares in issue18.90m
- ExchangeNASDAQ
- IndexS&P 600 Small Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.